Study confirms MiMedx dHACM allograft promotes cardiac repair following myocardial infarction
MiMedx Group, the leading regenerative medicine company, has announced that the latest peer-reviewed scientific study of the MiMedx dehydrated human amnion/chorion membrane (dHACM) allografts has been electronically published in the Journal of Cardiology & Cardiovascular Therapy.
The paper entitled ‘Dehydrated Human Amnion/Chorion Membrane Allograft promotes Cardiac Repair Following Myocardial Infarction’, was authored by Jeremy J. Lim, PhD; James Fonger, managing director; and Thomas J. Koob, PhD.
Acute myocardial infarction, more commonly known as heart attack, results in irreversible damage or cell death to cardiac tissue and may ultimately lead to heart failure. MiMedx PURION Processed dHACM allografts contain a unique array of regenerative cytokines, growth factors, and extracellular matrix involved in the regulation of tissue healing and modulation of inflammation, suggesting that dHACM grafts may hold promise in treating infarcted cardiac tissue following a heart attack In the scientific study, EpiFix and AmnioFix allografts were examined for the ability to prevent cardiac damage or promote healing in an in vivo mouse model of acute left ventricular myocardial infarction.
Parker H. Petit, chairman and chief executive officer, stated, “There is a critical need for novel and innovative therapies for effective treatments following myocardial infarction and to promote regeneration of cardiac tissues. At present, total heart transplants and left ventricular assist devices are the primary forms of treatment and these treatments have significant limitations and substantial costs. The ability of dHACM to attenuate damage or promote cardiac repair is worthy of very serious consideration in the cardiac care community. This scientific study is the first of its kind and the first published report confirming that dHACM may have positive effects in protecting cardiac tissue or promoting repair following acute myocardial infarction or heart attack.”
“Treatment with dHACM in this animal model improved cardiac repair following myocardial infarction through multiple paracrine effects, including through improved cell survival, enhanced vascularization, and recruitment of autologous stem cells within the infarcted cardiac tissue,” noted Thomas J. Koob, chief scientific officer. “Follow up studies will be conducted to include demonstrating improvement of important outcomes such as left ventricular dimensions, contractility and ejection volume.”
“In the study, dHACM allografts appeared to promote cardiac repair after myocardial infarction by reducing the size of fibrotic scaring in the mouse model. Study results such as the stimulated increase in positive stem cells, cell survival and vascularization in infarcted cardiac tissue, suggest that treatment with dHACM may improve cardiac repair through improved blood supply and recruitment of autologous stem cells,” concluded Petit.